FLT3LG and neoplasm: Pretreatment of vaccinated mice with FLT3-L to encourage DC maturation transiently improved the vaccine response, with a significantly reduced tumor burden at day 20 post-treatment compared to the vaccine group that was not administered FLT3-L.